AU652016B2 - Treatment for tissue ulceration - Google Patents

Treatment for tissue ulceration

Info

Publication number
AU652016B2
AU652016B2 AU91351/91A AU9135191A AU652016B2 AU 652016 B2 AU652016 B2 AU 652016B2 AU 91351/91 A AU91351/91 A AU 91351/91A AU 9135191 A AU9135191 A AU 9135191A AU 652016 B2 AU652016 B2 AU 652016B2
Authority
AU
Australia
Prior art keywords
alkyl
ulceration
residue
cornea
tryptophan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU91351/91A
Other languages
English (en)
Other versions
AU9135191A (en
Inventor
Richard E. Galardy
Damian Grobelny
Gregory Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of AU9135191A publication Critical patent/AU9135191A/en
Application granted granted Critical
Publication of AU652016B2 publication Critical patent/AU652016B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Meat And Fish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU91351/91A 1990-11-21 1991-11-21 Treatment for tissue ulceration Ceased AU652016B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/616,021 US5114953A (en) 1990-11-21 1990-11-21 Treatment for tissue ulceration
US616021 1990-11-21
PCT/US1991/008721 WO1992009282A1 (fr) 1990-11-21 1991-11-21 Traitement contre les ulcerations tissulaires

Publications (2)

Publication Number Publication Date
AU9135191A AU9135191A (en) 1992-06-25
AU652016B2 true AU652016B2 (en) 1994-08-11

Family

ID=24467733

Family Applications (1)

Application Number Title Priority Date Filing Date
AU91351/91A Ceased AU652016B2 (en) 1990-11-21 1991-11-21 Treatment for tissue ulceration

Country Status (9)

Country Link
US (1) US5114953A (fr)
EP (1) EP0558681B1 (fr)
JP (1) JPH06102626B2 (fr)
AT (1) ATE164767T1 (fr)
AU (1) AU652016B2 (fr)
CA (1) CA2096223C (fr)
DE (1) DE69129236T2 (fr)
ES (1) ES2115668T3 (fr)
WO (1) WO1992009282A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661289B2 (en) * 1990-11-21 1995-07-20 Richard E. Galardy Improved matrix metalloprotease inhibitors
AU662504B2 (en) * 1990-11-21 1995-09-07 Richard E. Galardy Improved matrix metalloprotease inhibitors

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5270326A (en) * 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5889058A (en) * 1990-12-03 1999-03-30 Celltech Limited Peptidyl derivatives
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08511509A (ja) * 1993-04-07 1996-12-03 グリコメド・インコーポレイテッド 合成マトリックスメタロプロテアーゼ阻害剤およびその用途
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
WO1995032944A1 (fr) * 1994-05-28 1995-12-07 British Biotech Pharmaceuticals Limited Acide succinyle hydroxamique, acide n-formyl-n-hydroxy amino carboxylique et derives amides de l'acide succinique en tant qu'inhibiteurs des metalloproteases
BR9609883A (pt) * 1995-08-08 1999-03-23 Fibrogen Inc Composto tendo efeito inibidor em proteinase c composição farmacéutica e processo para tratar doenças relacionadas com a produção inapropriada ou desregulada de colágeno
AU3729397A (en) * 1996-08-16 1998-03-06 Warner-Lambert Company Butyric acid matrix metalloproteinase inhibitors
EP1087937A1 (fr) * 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
US6187907B1 (en) 1998-08-31 2001-02-13 James Chen Triple helix coil template having a biologically active ligand
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
WO2003094954A1 (fr) * 2001-09-25 2003-11-20 Quick Med Technologies, Inc. Composition et procede servant a minimiser ou a eviter les effets nefastes de vesicants
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2003101381A2 (fr) * 2002-05-29 2003-12-11 Merck & Co., Inc. Composes 1,2 diamido cycloalkyle bloqueurs des canaux sodiques
US20080139512A1 (en) * 2002-09-25 2008-06-12 Quick-Med Technologies, Inc. Method for minimizing or avoiding adverse effects of vesicants
US20050107306A1 (en) * 2003-05-16 2005-05-19 Barr Philip J. Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors
AU2004263900A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
DK1684719T3 (da) * 2003-11-14 2012-01-30 Baxter Int Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
EP1737499A4 (fr) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc Traitement de la bronchopneumopathie chronique obstructive par inhalation a faible dose d'inhibiteur de protease
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0703677D0 (en) * 2007-02-26 2007-04-04 Surface Therapeutics Ltd Novel compounds
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291048A (en) * 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
JPS5758626A (en) * 1980-09-26 1982-04-08 Rikagaku Kenkyusho Carcinostatic agent
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
US4558034A (en) * 1984-01-31 1985-12-10 The Board Of Trustees Of The University Of Kentucky Inhibitors of bacterial collagenase
EP0159396B1 (fr) * 1984-04-12 1990-06-27 G.D. Searle & Co. Dérivés carboxyalkyl peptides
US4698342A (en) * 1985-07-16 1987-10-06 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
JPH01146896A (ja) * 1987-12-04 1989-06-08 Fuji Yakuhin Kogyo Kk 新規なペプチジルヒドロキサム酸誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661289B2 (en) * 1990-11-21 1995-07-20 Richard E. Galardy Improved matrix metalloprotease inhibitors
AU662504B2 (en) * 1990-11-21 1995-09-07 Richard E. Galardy Improved matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
AU9135191A (en) 1992-06-25
WO1992009282A1 (fr) 1992-06-11
EP0558681A4 (en) 1993-11-18
US5114953A (en) 1992-05-19
ES2115668T3 (es) 1998-07-01
CA2096223C (fr) 2002-09-24
EP0558681A1 (fr) 1993-09-08
DE69129236D1 (de) 1998-05-14
JPH06102626B2 (ja) 1994-12-14
ATE164767T1 (de) 1998-04-15
CA2096223A1 (fr) 1992-05-22
EP0558681B1 (fr) 1998-04-08
JPH05508164A (ja) 1993-11-18
DE69129236T2 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
AU652016B2 (en) Treatment for tissue ulceration
US5183900A (en) Matrix metalloprotease inhibitors
US5189178A (en) Matrix metalloprotease inhibitors
AU661289B2 (en) Improved matrix metalloprotease inhibitors
US5270326A (en) Treatment for tissue ulceration
US5696147A (en) Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5773438A (en) Synthetic matrix metalloprotease inhibitors and use thereof
JPH11502523A (ja) ラクタム含有ヒドロキサム酸誘導体、その製造およびメタロプロテアーゼ基質の阻害剤としての使用
JP2004115531A (ja) 置換環状アミンメタロプロテアーゼ阻害剤
AU6554294A (en) Synthetic matrix metalloprotease inhibitors and uses thereof
AU8311898A (en) Synthetic matrix metalloprotease inhibitors and uses thereof

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired